Shanghai, November 10, 2023 – Leadingtac (Leading Tac Pharmaceutical Co., Ltd) representatives Dr. Yan Feng, CEO and Dr. Zhengqing Ye, Senior Director of Chemistry, presented the onsite BioDuro-Sundia chemistry team with The Leadingtac 2023 Best Partner Award during a welcome visit to the BioDuro-Sundia Zhangjiang R&D Center in Shanghai recently. BioDuro-Sundia representatives Dr. Jiong Chen, Senior Vice President of Chemistry, Dr. Jinrui Yang, Director of Chemistry, Wenjie Luo, Group Leader I of Chemistry, and ZhenHan Lei, Senior Director of Business Development were honored to attend the ceremony and receive this award.

Leadingtac is a preclinical-stage company dedicated to the discovery and development of First-in-class/Best-in-class small molecule innovative drugs. The company's first pipeline based on its Nano-SPUD® platform was officially approved by  FDA in May 2023 to enter Phase 1 clinical trials, also it officially received approval from NMPA for Phase I clinical trial in this October. The pipeline has global intellectual property rights, and the current research and development progress is the first in China and the second around the world. In addition, other R&D pipelines are also progressing smoothly.

Dr. Yan Feng, CEO of Leadingtac, praised the BioDuro-Sundia chemistry team’s efficient service capabilities, “Even for very difficult exploratory projects, the chemistry team of BioDuro-Sundia delivered beyond expectations, which gave us great peace of mind and confidence in our future path together!”

BioDuro-Sundia representative Dr. Jinrui Yang, Director of Chemistry, expressed, “We are gratitude to Leadingtac for initiating this ceremony of mutual recognition and trust, and we will continue to complete every project with high standards and quality". Dr. Jiong Chen, Senior Vice President of Chemistry, added, "We are very pleased to see that Leadingtac has recently achieved another important milestone, with the first pipeline officially approved by NMPA for  phase I clinical trials this year, after having received FDA approval for clinical trials! We sincerely congratulate Leadingtac and look forward to seeing the rest of Leadingtac 's R&D pipeline progress smoothly. We will support Leadingtac discover and develop new drugs with our continued high quality and efficient services." 

BioDuro-Sundia’s commitment is to provide global biopharmaceutical companies with a complete one-stop service platform for new drug R&D services and professional technical support. Equipped with advanced research facilities and a team of more than 1,200 professional chemists, the BioDuro-Sundia Chemistry Department has provided drug R&D services at different stages for more than 330 pharmaceutical companies around the world, including many of the world's top 20 pharmaceutical companies and advanced biotechnology startups. Looking ahead, BioDuro-Sundia takes a quality-first approach and treats each program with care. BioDuro-Sundia works together with clients to synergize and innovate, to achieve win-win situations, and to move forward together.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 9 global sites across 6 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit

About Leadingtac

Founded in 2019, Leadingtac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of First-in-class/Best-in-class small molecule innovative therapies using Protein Degradation (TPD) drug development platform with a focus on autoimmune and oncology, two therapeutic areas with great clinical unmet needs: autoimmune disease and oncology, providing breakthrough therapeutic solutions for patients. Located in Zhangjiang Science City, Shanghai, China, Leadingtac has nearly 1000 square meters of laboratory and office space, 20 employees, and has raised nearly CNY¥100 million in funding since its inception 4 years ago.

We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all